Highly sensitive system and method for analysis of troponin
The invention provides methods, compositions, kits, and systems for the sensitive detection of cardiac troponin, Such methods, compositions, kits, and systems are useful in diagnosis, prognosis, and determination of methods of treatment in conditions that involve release of cardiac troponin.
1. A method for determining the presence or amount of cardiac troponin selected from the group consisting of cardiac I (cTnI), cardiac troponin T (cTnT), complexes of cTnI, complexes of cTnT, and combinations thereof, in a blood, serum or plasma sample from an apparently healthy human subject, the method comprising an assay having a sensitivity for cardiac troponin of less than 3 pg/mL and comprising:
(a) contacting the cardiac troponin from the sample with a label comprising a binding partner for the cardiac troponin and a detectable moiety; and
(b) counting individual digital events representing binding of the binding partner to single molecules of the cardiac troponin, wherein each individual digital event comprises a signal representing a single molecule of troponin in the sample;
(c) determining a total signal as a sum of the individual digital events and relating the sum to the presence or a concentration of cardiac troponin in the sample.
2. The method of claim 1 , wherein the total signal relates to a concentration of cardiac troponin in a sample of less than about 10 pg/mL.
3. The method of claim 1 , wherein the total signal relates to a concentration of cardiac troponin in a sample of less than about 5 pg/mL.
4. The method of claim 1 , wherein the total signal relates to a concentration of cardiac troponin in a sample of less than about 3 pg/mL.
5. The method of claim 1 , wherein the signal is a photon signal.
6. The method of claim 5 , wherein the photon signal is a fluorescent signal.
7. The method of claim 1 , wherein the detectable moiety comprises a fluorescent molecule.
8. The method of claim 1 , wherein the cardiac troponin is cTnI.
9. The method of claim 1 , wherein the cardiac troponin is cTnT.
10. The method of claim 1 , wherein the cardiac troponin is cTnI and complexes of cTnI.
11. The method of claim 1 , wherein the cardiac troponin is cTnT and complexes of cTnT.
12. The method of claim 1 , further comprising eluting the label from the troponin prior to counting the individual digital events.
13. The method of claim 1 wherein step b comprises determining the detectable moiety in an interrogation space defined by the focus of a beam from an electromagnetic radiation source.
14. The method of claim 13 wherein the counting the digital events comprises detecting the detectable moiety in an analyzer comprising:
(a) an electromagnetic radiation detector operably connected to the interrogation space for measuring an electromagnetic characteristic of the detectable moiety; and
(b) a microscope objective lens situated between the interrogation space and the detector.
15. An assay for determining the presence or amount of cardiac troponin selected from the group consisting of cardiac I (cTnI), cardiac troponin T (cTnT), complexes of cTnI, complexes of cTnT, and combinations thereof, in a blood, serum or plasma sample from an apparently healthy human subject, the method comprising:
i) labeling the cardiac troponin from the sample with a label comprising a binding partner for the troponin and a detectable moiety; and
ii) counting individual digital events representing binding of the binding partner to the cardiac troponin, wherein each individual digital event is provided as a signal representing a single molecule of cardiac troponin in the sample;
iii) determining a total signal as a sum of the digital events and relating the sum to a concentration of cardiac troponin in the sample, wherein the determining the total signal and relating the sum to the concentration of troponin comprises a sensitivity for cardiac troponin in the sample of less than 3 pg/mL.
16. The assay of claim 15 , wherein the sensitivity comprises a coefficient of variation of less than about 10%.
17. The assay of claim 15 , wherein the total signal relates to a concentration of cardiac troponin in a sample of less than about 10 pg/mL.
18. The assay of claim 15 , wherein the total signal relates to a concentration of cardiac troponin in a sample of less than about 5 pg/mL.
19. The assay of claim 15 , wherein the total signal relates to a concentration of cardiac troponin in a sample of less than about 3 pg/mL.
20. The assay of claim 15 , wherein the signal is a photon signal.
21. The assay of claim 20 , wherein the photon signal is a fluorescent signal.
22. The assay of claim 15 , wherein the detectable moiety comprises a fluorescent molecule.
23. The assay of claim 15 , wherein the cardiac troponin is cTnI.
24. The assay of claim 15 , wherein the cardiac troponin is cTnT.
25. The assay of claim 15 , wherein the cardiac troponin is cTnI and complexes of cTnI.
26. The assay of claim 15 , wherein the cardiac troponin is cTnT and complexes of cTnT.
27. A method for determining the presence or amount of cardiac troponin selected from the group consisting of cardiac I (cTnI), cardiac troponin T (cTnT), complexes of cTnI, complexes of cTnT, and combinations thereof, in a blood, serum or plasma sample from an apparently healthy human subject, the method comprising:
i) counting individual binding events representing binding of a binding partner to single molecules of cardiac troponin from the sample;
ii) determining a total signal as a sum of the binding events and relating the sum to a concentration of cardiac troponin in the sample, wherein the determining the total signal and relating the sum to the concentration of troponin comprises a sensitivity for cardiac troponin in the sample of less than 3 pg/mL.
28. The method of claim 27 , wherein the counting individual binding events comprises detecting a label corresponding to the single molecules of the cardiac troponin from the sample.
29. The method of claim 28 , wherein the label comprises the binding partner for the cardiac troponin and a detectable moiety.
30. The method of claim 29 , wherein the detectable moiety is a photon emitting moiety.
31. The method of claim 30 , wherein the photon emitting moiety is a fluorescent moiety.
32. The method of claim 27 , wherein the binding partner comprises an antibody or a binding portion thereof and the detectable moiety is a fluorescent moiety.
33. The method of claim 27 , wherein the total signal relates to a concentration of cardiac troponin in a sample of less than about 10 pg/mL.
34. The method of claim 27 , wherein the total signal relates to a concentration of cardiac troponin in a sample of less than about 5 pg/mL.
35. The method of claim 27 , wherein the total signal relates to a concentration of cardiac troponin in a sample of less than about 3 pg/mL.
36. The method of claim 27 , wherein the cardiac troponin is cTnI.
37. The method of claim 27 , wherein the cardiac troponin is cTnT.
38. The method of claim 27 , wherein the cardiac troponin is cTnI and complexes of cTnI.
39. The method of claim 27 , wherein the cardiac troponin is cTnT and complexes of cTnT.
40. The method of claim 27 , wherein the determining the total signal and relating the sum to the concentration of troponin comprises a sensitivity for cardiac troponin in the sample of less than 3 pg/mL.
41. The assay of claim 27 , wherein the sensitivity comprises a coefficient of variation of less than about 10%.